Trials in Philadelphia, Pennsylvania
Here are the top 10 medical studies for lung cancer in Philadelphia, Pennsylvania
Popular Filters
Phase 3 Trials
Ramucirumab + Pembrolizumab vs Chemotherapy for Non-Small Cell Lung Cancer
Recruiting2 awardsPhase 3
Newark, Delaware
This trial compares ramucirumab+pembrolizumab vs chemo for non-small cell lung cancer. Ramucirumab+pembrolizumab may stop tumors from growing and spreading, while chemo kills/stops cells from dividing/spreading. Results may help find out if this combo is more effective than chemo.
Chemotherapy
High-Dose Radiation + Chemotherapy and Immunotherapy for Non-Small Cell Lung Cancer
Recruiting2 awardsPhase 3
West Reading, Pennsylvania
This trial tests whether adding a precise form of radiation therapy to the usual treatment improves outcomes for patients with advanced lung cancer that can't be operated on. The goal is to see if this combination helps patients live longer and prevents cancer from worsening. This form of radiation therapy has shown promise in improving survival rates in patients with various stages of lung cancer.
Alkylating agents
Furmonertinib for Non-Small Cell Lung Cancer
Recruiting2 awardsPhase 3
Langhorne, Pennsylvania
This trial is testing furmonertinib at two different doses to treat a specific type of lung cancer. It targets patients with advanced or metastatic non-squamous NSCLC who have a particular genetic mutation. The medication works by blocking a protein that helps cancer cells grow, potentially slowing down or stopping the cancer.
Anti-tumor antibiotic
ONC-392 vs Chemotherapy for Lung Cancer
Recruiting2 awardsPhase 3
East Brunswick, New Jersey
This trial is testing gotistobart, a new drug that helps the immune system fight advanced lung cancer in patients who haven't responded to other treatments. It works by blocking a protein that allows cancer cells to hide from the immune system.
Monoclonal Antibodies
Fianlimab + Cemiplimab for Non-Small Cell Lung Cancer
Recruiting0 awardsPhase 2 & 3
Pennington, New Jersey
This trial is testing a new drug combination for patients with advanced lung cancer. It aims to see if using two drugs together is more effective than one alone. The study also looks at side effects, how the drugs are processed in the body, and their impact on quality of life.
Trials With No Placebo
Ramucirumab + Pembrolizumab vs Chemotherapy for Non-Small Cell Lung Cancer
Recruiting2 awardsPhase 3
Newark, Delaware
This trial compares ramucirumab+pembrolizumab vs chemo for non-small cell lung cancer. Ramucirumab+pembrolizumab may stop tumors from growing and spreading, while chemo kills/stops cells from dividing/spreading. Results may help find out if this combo is more effective than chemo.
Monoclonal Antibodies
AG-01 Antibody Therapy for Advanced Cancers
Recruiting1 awardPhase 1
Baltimore, Maryland
This trial tests AG01, a protein that targets PGRN/GP88 on cancer cells, in patients with advanced cancers who haven't responded to other treatments. The goal is to see if AG01 can help control cancer growth by binding to PGRN/GP88. AG01 is a treatment that has been shown to reduce the growth and spread of certain cancer cells.
Chemotherapy
High-Dose Radiation + Chemotherapy and Immunotherapy for Non-Small Cell Lung Cancer
Recruiting2 awardsPhase 3
West Reading, Pennsylvania
This trial tests whether adding a precise form of radiation therapy to the usual treatment improves outcomes for patients with advanced lung cancer that can't be operated on. The goal is to see if this combination helps patients live longer and prevents cancer from worsening. This form of radiation therapy has shown promise in improving survival rates in patients with various stages of lung cancer.
Monoclonal Antibodies
GT103 + Pembrolizumab for Lung Cancer
Recruiting1 awardPhase 2
Berkeley Heights, New Jersey
This trial tests the safety and tolerability of combining GT103, a new drug, with pembrolizumab, an immune-boosting cancer treatment, in adults with advanced lung cancer that has returned or not responded to previous treatments. Pembrolizumab is an immune-boosting treatment that has shown effectiveness in patients with lung cancer and has been tested with other treatments.
View More Related Trials
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.